 Michael Berquist Ii
Concepts (120)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Stimulants | 8 | 2020 | 209 | 3.120 |
Why?
| | Methamphetamine | 7 | 2021 | 194 | 2.800 |
Why?
| | Locomotion | 7 | 2019 | 84 | 2.360 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 4 | 2020 | 37 | 2.080 |
Why?
| | Discrimination Learning | 3 | 2020 | 64 | 1.750 |
Why?
| | Ethanol | 3 | 2024 | 336 | 1.540 |
Why?
| | Benzodioxoles | 5 | 2019 | 40 | 1.490 |
Why?
| | Pyrrolidines | 5 | 2019 | 67 | 1.480 |
Why?
| | Alcohol Drinking | 2 | 2024 | 227 | 1.440 |
Why?
| | Rats | 16 | 2024 | 3292 | 1.280 |
Why?
| | Rats, Sprague-Dawley | 11 | 2024 | 1585 | 0.960 |
Why?
| | Animals | 23 | 2024 | 13124 | 0.940 |
Why?
| | Telemetry | 3 | 2020 | 29 | 0.860 |
Why?
| | Behavior, Animal | 2 | 2015 | 178 | 0.840 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 2023 | 28 | 0.840 |
Why?
| | Bile Ducts | 2 | 2020 | 49 | 0.830 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 182 | 0.780 |
Why?
| | Alcoholism | 2 | 2022 | 235 | 0.780 |
Why?
| | Dextroamphetamine | 3 | 2017 | 39 | 0.760 |
Why?
| | Amphetamines | 1 | 2021 | 29 | 0.750 |
Why?
| | Buprenorphine | 1 | 2023 | 145 | 0.740 |
Why?
| | Naltrexone | 1 | 2021 | 59 | 0.730 |
Why?
| | Dopamine | 3 | 2019 | 175 | 0.720 |
Why?
| | Conditioning, Operant | 2 | 2020 | 109 | 0.680 |
Why?
| | Serotonin | 2 | 2018 | 151 | 0.670 |
Why?
| | Stereotyped Behavior | 1 | 2019 | 17 | 0.670 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 22 | 0.670 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 393 | 0.620 |
Why?
| | Psychoses, Substance-Induced | 1 | 2018 | 7 | 0.590 |
Why?
| | Cyclohexylamines | 1 | 2017 | 4 | 0.580 |
Why?
| | Cyclohexanones | 1 | 2017 | 5 | 0.580 |
Why?
| | Phencyclidine | 1 | 2017 | 35 | 0.570 |
Why?
| | Choice Behavior | 2 | 2019 | 83 | 0.560 |
Why?
| | Glutamic Acid | 1 | 2018 | 113 | 0.560 |
Why?
| | Male | 19 | 2024 | 25907 | 0.550 |
Why?
| | Cannabinoids | 1 | 2018 | 105 | 0.520 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 1372 | 0.520 |
Why?
| | Rats, Long-Evans | 3 | 2023 | 26 | 0.510 |
Why?
| | Enzyme Inhibitors | 1 | 2017 | 377 | 0.490 |
Why?
| | Hallucinogens | 3 | 2021 | 65 | 0.470 |
Why?
| | Arginine Vasopressin | 1 | 2013 | 13 | 0.440 |
Why?
| | Memory | 1 | 2013 | 114 | 0.410 |
Why?
| | Cocaine | 4 | 2019 | 182 | 0.410 |
Why?
| | Attention | 1 | 2013 | 172 | 0.410 |
Why?
| | Drug Interactions | 2 | 2021 | 206 | 0.310 |
Why?
| | Pregnancy | 2 | 2024 | 2452 | 0.260 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2024 | 7 | 0.260 |
Why?
| | Mice | 5 | 2022 | 5687 | 0.250 |
Why?
| | Female | 8 | 2024 | 27081 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2024 | 15 | 0.230 |
Why?
| | Morphine | 1 | 2024 | 101 | 0.220 |
Why?
| | Liver | 2 | 2020 | 1132 | 0.220 |
Why?
| | Ligation | 2 | 2020 | 62 | 0.220 |
Why?
| | Receptors, Opioid, mu | 1 | 2023 | 46 | 0.210 |
Why?
| | Adrenergic Uptake Inhibitors | 2 | 2019 | 15 | 0.210 |
Why?
| | Serotonin 5-HT2 Receptor Agonists | 1 | 2021 | 7 | 0.190 |
Why?
| | Alcohol Deterrents | 1 | 2021 | 11 | 0.190 |
Why?
| | Periplaneta | 1 | 2021 | 1 | 0.180 |
Why?
| | Cockroaches | 1 | 2021 | 3 | 0.180 |
Why?
| | Central Nervous System Depressants | 1 | 2021 | 80 | 0.180 |
Why?
| | Self Administration | 2 | 2019 | 97 | 0.180 |
Why?
| | Sex Characteristics | 2 | 2019 | 198 | 0.170 |
Why?
| | Serotonin Agents | 1 | 2020 | 13 | 0.170 |
Why?
| | Rodentia | 1 | 2020 | 16 | 0.170 |
Why?
| | Liver Diseases | 1 | 2020 | 80 | 0.170 |
Why?
| | Injections, Intraperitoneal | 1 | 2019 | 59 | 0.170 |
Why?
| | Random Allocation | 1 | 2020 | 289 | 0.160 |
Why?
| | Impulsive Behavior | 1 | 2019 | 76 | 0.160 |
Why?
| | Psychotropic Drugs | 1 | 2019 | 76 | 0.150 |
Why?
| | Motor Activity | 1 | 2019 | 225 | 0.150 |
Why?
| | Neurotransmitter Uptake Inhibitors | 1 | 2018 | 6 | 0.150 |
Why?
| | Lysergic Acid Diethylamide | 1 | 2017 | 7 | 0.140 |
Why?
| | Receptors, Dopamine | 1 | 2017 | 21 | 0.140 |
Why?
| | Fenfluramine | 1 | 2017 | 8 | 0.140 |
Why?
| | Premedication | 1 | 2017 | 17 | 0.140 |
Why?
| | Dopamine Agents | 1 | 2017 | 18 | 0.140 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 29 | 0.140 |
Why?
| | Analgesics, Opioid | 1 | 2023 | 575 | 0.140 |
Why?
| | Body Temperature | 1 | 2017 | 67 | 0.140 |
Why?
| | Heart Rate | 1 | 2019 | 307 | 0.140 |
Why?
| | GTP-Binding Proteins | 1 | 2017 | 91 | 0.140 |
Why?
| | Quinuclidines | 1 | 2017 | 40 | 0.140 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2017 | 51 | 0.140 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2017 | 168 | 0.130 |
Why?
| | Blood Pressure | 1 | 2019 | 531 | 0.130 |
Why?
| | Schizophrenia | 1 | 2018 | 258 | 0.130 |
Why?
| | Infant, Newborn | 1 | 2023 | 2749 | 0.130 |
Why?
| | Brain | 1 | 2024 | 1319 | 0.130 |
Why?
| | Polydipsia | 1 | 2015 | 1 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2018 | 154 | 0.130 |
Why?
| | Fluoxetine | 1 | 2015 | 42 | 0.120 |
Why?
| | Anti-Anxiety Agents | 1 | 2015 | 34 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2017 | 1436 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 370 | 0.110 |
Why?
| | Rats, Brattleboro | 1 | 2013 | 1 | 0.110 |
Why?
| | Reaction Time | 1 | 2013 | 214 | 0.100 |
Why?
| | Cognition | 1 | 2013 | 346 | 0.090 |
Why?
| | Humans | 3 | 2023 | 50503 | 0.090 |
Why?
| | Cerebellum | 1 | 2022 | 131 | 0.050 |
Why?
| | Lethal Dose 50 | 1 | 2021 | 12 | 0.050 |
Why?
| | Hippocampus | 1 | 2022 | 222 | 0.040 |
Why?
| | Corpus Striatum | 1 | 2019 | 51 | 0.040 |
Why?
| | Alkaloids | 1 | 2019 | 28 | 0.040 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2019 | 59 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 52 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 224 | 0.040 |
Why?
| | Cyclohexanols | 1 | 2017 | 21 | 0.040 |
Why?
| | Cricetulus | 1 | 2017 | 97 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2017 | 104 | 0.040 |
Why?
| | CHO Cells | 1 | 2017 | 118 | 0.040 |
Why?
| | Naphthalenes | 1 | 2017 | 121 | 0.030 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2017 | 123 | 0.030 |
Why?
| | Adrenergic alpha-2 Receptor Antagonists | 1 | 2015 | 3 | 0.030 |
Why?
| | Yohimbine | 1 | 2015 | 10 | 0.030 |
Why?
| | Food Deprivation | 1 | 2015 | 30 | 0.030 |
Why?
| | Drinking Water | 1 | 2015 | 11 | 0.030 |
Why?
| | Protein Binding | 1 | 2017 | 654 | 0.030 |
Why?
| | Drinking | 1 | 2015 | 38 | 0.030 |
Why?
| | Indoles | 1 | 2017 | 278 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2015 | 177 | 0.030 |
Why?
|
|
Berquist Ii's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|